Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib after progression on alectinib or ceritinib in ALK-positive advanced NSCLC
NL-OMON49812Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoint: Confirmed objective response rate. Started Oct 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49812.